US 12,234,288 B2
Immunogenic arginase 2 polypeptides
Mads Hald Andersen, Nærum (DK)
Assigned to IO Biotech ApS, Copenhagen (DK)
Appl. No. 17/293,325
Filed by IO Biotech ApS, Copenhagen (DK)
PCT Filed Nov. 14, 2019, PCT No. PCT/EP2019/081369
§ 371(c)(1), (2) Date May 12, 2021,
PCT Pub. No. WO2020/099582, PCT Pub. Date May 22, 2020.
Claims priority of application No. 1818576 (GB), filed on Nov. 14, 2018.
Prior Publication US 2021/0403566 A1, Dec. 30, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C12N 9/78 (2006.01)
CPC C07K 16/2818 (2013.01) [A61K 39/001154 (2018.08); A61P 35/00 (2018.01); C12N 9/78 (2013.01); A61K 2039/505 (2013.01); C12Y 305/03001 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A composition comprising a polypeptide which is animmunogenic fragment of human Arginase2 (SEQ ID NO: 51) that comprises or consists of a sequence of at least 9 consecutive amino acids of SEQ ID NO: 51 which includes at least the amino acids at positions 21, 22 and 23 of SEQ ID NO: 51, wherein the polypeptide has a maximum length of 50 amino acids and an adjuvant.